Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred revenue by Year
Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M) ($M)
Moderna Deferred revenue: $145M in FY2025, up 530.4% from a year earlier.
Latest, FY2025
145
Period ended Dec 31, 2025
Change on a year earlier
+530.4%
23 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 145 | +530.4% | Form 10-Q (filed 2026-07-31) ↗ |
| FY2024 | Dec 31, 2024 | 23 | – | Form 10-K (filed 2026-02-20) ↗ |
Cite this data
StockData. (2026). Moderna Deferred revenue ($M), annual FY2024–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-other
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.